Integrated Multi‐Omics and Experimental Validation Unveil the GZMK/NF‐κB Axis Driving Inflammation and Fibroblast Proliferation in Rosacea: A Novel Drug Target Selection Strategy
The FASEB Journal · 2025
DOI: 10.1096/fj.202502071r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Jing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Rosacea, NF-kappa B, Cell Proliferation, Inflammation. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Ministry of Health of China | CJFH | China-Japan Friendship Hospital Youth Science and Technology Excellence Project, Outstanding Youth Project of Natural Science Foundation of Anhui Province, MOST | National Key Research and Development Program of China (NKPs).
Abstract (Originalsprache)
The prevalence of rosacea is high, while the drug options remain limited. Mendelian randomization (MR) is an effective way to prioritize plasma proteins as novel drug targets based on their causal effects on rosacea. The plasma proteins were categorized into different levels of drug targets by the MR and Bayesian colocalization analysis. Their genetic and protein expression was investigated using an RNA sequencing dataset and experiments in vitro and in vivo. MR and colocalization identified Granzyme K (GZMK) as a drug target, whose expression increased in the affected samples. A novel mouse model of rosacea was established by GZMK, mimicking rosacea‐like symptoms both in vitro and in vivo. GZMK also promoted cell proliferation and inflammatory factors (including IL‐1β, IL‐6, and TNFα) production in fibroblasts through activating the NF‐κB pathway in vitro. Our research identified a novel protein involved in rosacea pathogenesis, elucidated the underlying mechanisms, and advanced the development of potential rosacea treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, China-Japan Friendship Hospital, Beijing, China.
- Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Förderung
- Ministry of Health of China | CJFH | China-Japan Friendship Hospital Youth Science and Technology Excellence Project
- Outstanding Youth Project of Natural Science Foundation of Anhui Province
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China (NSFC)
- National High Level Hospital Clinical Research Funding
- China-Japan Friendship Hospital Youth Science and Technology Excellence Project
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Bi, L., Zhao, H., Xu, Z., Zhuang, Z., Chen, K., Ouyang, H., Xu, J., Sheng, Y., Wang, Z., & Cui, Y. (2025). Integrated Multi‐Omics and Experimental Validation Unveil the GZMK/NF‐κB Axis Driving Inflammation and Fibroblast Proliferation in Rosacea: A Novel Drug Target Selection Strategy. The FASEB Journal. https://doi.org/10.1096/fj.202502071r
Vancouver
Wang J, Bi L, Zhao H, Xu Z, Zhuang Z, Chen K, et al. Integrated Multi‐Omics and Experimental Validation Unveil the GZMK/NF‐κB Axis Driving Inflammation and Fibroblast Proliferation in Rosacea: A Novel Drug Target Selection Strategy. The FASEB Journal. 2025. doi:10.1096/fj.202502071r
BibTeX
@article{Wang2025,
author = {Wang, Jing and Bi, Lingbo and Zhao, Hanqing and Xu, Zining and Zhuang, Zhou and Chen, Kejun and Ouyang, Hongfei and Xu, Jingkai and Sheng, Yujun and Wang, Ziyi and Cui, Yong},
title = {Integrated Multi‐Omics and Experimental Validation Unveil the GZMK/NF‐κB Axis Driving Inflammation and Fibroblast Proliferation in Rosacea: A Novel Drug Target Selection Strategy},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202502071r}
}
EUVIMED